<DOC>
	<DOCNO>NCT00478738</DOCNO>
	<brief_summary>GSK961081 previously administer healthy subject nebulised formulation first part study conduct healthy subject propose bridge change nebulised DPI formulation GSK961081 administration patient . The second part study conduct COPD patient aim assess safety bronchodilator profile GSK961081 24 hour , 14 day dose .</brief_summary>
	<brief_title>A 2 Part Study Examining Doses Of GSK961081 In Healthy Volunteers And Then In COPD Patients</brief_title>
	<detailed_description>A study ass pharmacokinetics single escalate dos inhale GSK961081 DPI ( dual pharmacophore ) healthy subject ( Part 1 ) randomise , double-blind , double dummy , crossover ( incomplete block ) study assess safety , tolerability , pharmacodynamics ( pulmonary systemic ) pharmacokinetics 14 day dose inhaled GSK961081 DPI compare placebo tiotropium plus salmeterol patient COPD ( Part 2 ) .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Subject male female ( nonchild bear potential ) &gt; 40 year age &lt; 75 year age . Non child bear potential define physiologically incapable become pregnant , include female post menopausal ( 2 year without menses appropriate clinical history ie age , history vasomotor symptomsestradiol FSH level may check indicate ) female surgically sterile ( hysterectomy , tubal ligation bilateral oophorectomy . Subject diagnose COPD ( stage II ) accordance ATS/ERS guideline ( see Appendix 2 : COPD Guidelines ) . Subject smoker ex smoker history least 10 pack year ( 1 pack year= 20 cigarette smoke per day 1 year equivalent ) Subject FEV1/FVC &lt; 0.7 post bronchodilator ( salbutamol ) Subject FEV1 &lt; 80 % predict normal height , age , gender inhalation salbutamol Response ipratropium bromide define : Either increase FEV1 &gt; 12 % &gt; 150 mLwithin 2 hour follow inhalation 80 µcg ipratropium bromide screen visit Or : documented increase FEV1 &gt; 12 % &gt; 150 mL within 2 hour follow inhalation 80 µcg ipratropium bromide within 6 month screen increase FEV1 &gt; 6 % &gt; 100 mL within 2 h follow inhalation 80 mg ipratropium bromide screen visit ( order allow potential fluctuation response ipratropium bromide patient know responder ipratropium bromide ) Response salbutamol define : Either increase FEV1 &gt; 12 % &gt; 150 mL within 2 hour follow inhalation 400 mg salbutamol screen visit Or : documented increase FEV1 &gt; 12 % &gt; 150 mL within 2 hour follow inhalation 400 mg salbutamol within 6 month screen increase FEV1 &gt; 6 % &gt; 100 mL within 2 h follow inhalation 400 mg salbutamol screen visit ( order allow potential fluctuation response salbutamol patient know responder salbutamol ) Body mass index within range 1835 kilograms/metre² ( kg/m² ) . Subject able willing give write informed consent take part study . Subject available complete study measurement Subjects past present disease , judge Investigator medical monitor may affect outcome study safety subject Women pregnant lactate An unwillingness subject abstain sexual intercourse pregnant lactating woman ; unwillingness subject use condom/spermicide addition female partner use another form contraception IUD , diaphragm spermicide , oral contraceptive , injectable progesterone , subdermal implant tubal ligation woman could become pregnant time first dose study medication 90 day postdose The subject positive urine drug screen . A minimum list drug screen include Amphetamines , barbiturates , Cocaine , Opiates , Cannabinoids Benzodiazepines . The subject positive alcohol test ( breath urine ) predose . A history , suspect history , alcohol abuse within 6 month screen visit . A positive test hepatitis C antibody , hepatitis B surface antigen , HIV . The subject participate clinical study another New Chemical Entity within past 2 month participate clinical study drug previous month . The subject donate unit blood within 56 day intend donate within 56 day complete study . The subject claustrophobia may aggravate enter plethysmography cabinet . Subject FEV1 &lt; 50 % predicted age , height gender inhalation salbutamol . The subject diagnosis active tuberculosis , lung cancer , sarcoidosis , bronchiectasis , lung fibrosis , pulmonary hypertension primary diagnosis asthma The subject know allergy hypersensitivity ipratropium , salbutamol , tiotropium , salmeterol lactose A subject ipratropium , salbutamol , tiotropium and/or salmeterol contraindicate Subjects lung volume reduction surgery within 12 month screen Poorly control COPD define : Either : acute worsen COPD manage subject home treatment increase corticosteroid antibiotic 6 week screen Or : 2 exacerbation previous 12 month screen required course oral steroid antibiotic , and/or require hospitalisation Subject respiratory tract infection 4 week screen Subject require treatment inhaled cromolyn sodium , theophyline , oral beta agonist , nebulised anticholinergic leukotriene antagonist Subject unable abstain long act beta agonist 72 hour screen throughout dose period Subject unable abstain tiotropium 28 day screen throughout dose period Subject predict unable abstain short act inhaled beta agonist ( use rescue medication study ) 6 hour screen study visit , require , post dose lung function test complete give study day . Subject receive oral corticosteroid within 6 week screen Subject receive &gt; 1000 mg FP ( equivalent ) day inhale corticosteroid change dose within 6 week screen predict able maintain constant dose study Subject receive oxygen therapy nocturnal positive pressure treatment Subject prostate hypertrophy narrow angle glaucoma The subject unable use dose device correctly . Subject carcinoma complete remission least 5 year ( exception carcinoma situ cervix , squamous cell carcinoma basal cell carcinoma subject consider cure ) A history congestive heart failure , coronary insufficiency cardiac arrhythmia Abnormal 12 lead ECG abnormality either clinically significant may interfere QTc measurement A supine mean heart rate outside range 4090 beat per minute ( bpm ) screening . Elevated supine blood pressure high 160/95 screening . Subject receive diuretic and/ beta adrenergic antagonist . Subject serum potassium level reference range screening . Strict vegetarian ; Shiftworker unable comply study ; Inability understand protocol requirement , instruction studyrelated restriction ; nature , scope possible consequence study ; Unlikely complete study ; e.g. , uncooperative attitude , inability return Followup Visits ; Subject Investigator subinvestigator , research assistant , pharmacist , study coordinator , staff , relative thereof directly involve conduct study ; Vulnerable individual ( e.g. , person keep detention ) .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>b-agonist ,</keyword>
	<keyword>COPD .</keyword>
	<keyword>pharmacodynamic ,</keyword>
	<keyword>pharmacokinetic ,</keyword>
	<keyword>anti muscarinic ,</keyword>
</DOC>